Drugs / Insulin Tregopil
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03392961 | Mar → Jul 2014 | type 2 diabetes mellitus | Biocon Limited | Completed | No outcome recorded |
| Phase 1 | NCT01035801 | Aug 2010 → Mar 2011 | type 1 diabetes mellitus | Biocon Limited | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03430856 | Dec 2017 → Feb 2019 | type 2 diabetes mellitus | Biocon Limited | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04141423 Comparator | Oct 2019 → Apr 2021 | type 1 diabetes mellitus | Biocon Limited | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin Tregopil | “This is an open label Phase II/III study to evaluate the efficacy and safety of test drug, Insulin Tregopil (IN-105) compared with Insulin Aspart (IAsp) in Type 2 Diabetes...” NCT03430856 ↗1“IN-105 (Insulin Tregopil)” NCT03392961 ↗ |
| Known as | IN-105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01035801 ↗ |
| Known as | Insulina tregopilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108305 ↗ |
| Known as | Insuline tregopil | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108305 ↗ |
| Known as | Tregopil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03430856 ↗ |
| Action | Activate | “Insulin receptor agonist” CHEMBL2108305 ↗ |
| Modality | Protein / enzyme biologic | “oral insulin tregopil” PMID 31392840 ↗ Aug 2019 |
| Route | Oral | “The purpose of this study is to see whether IN-105 (oral insulin) is able to control increase in blood glucose after eating a meal.” NCT01035801 ↗ |
| Target | INSR | “Insulin receptor agonist” CHEMBL2108305 ↗ |